Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
Twitter Feed
-
See how a new @Microsoft #AIforHealth grant is advancing our search for new COVID-19 therapies as part of UCB’s digital business transformation. https://t.co/F0s7gjuJxQ #COVIDmoonshot #MSIgnite
— UCB News (@ucb_news) 23.09.2020 -
Proud to have been featured at the #MSIgnite event. Thank you for the great collaboration #AIforHealth. https://t.co/EgCF83ahPS
— UCB News (@ucb_news) 23.09.2020 -
In the case of immune thrombocytopenia (ITP) the immune system attacks blood cells, specifically platelets. This puts patients at risk of bleeding. We are dedicated to developing new solutions that can help improve health outcomes for people living with #
— UCB News (@ucb_news) 22.09.2020
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
